Abstract Purpose To evaluate the efficacy and safety of PHPV in the treatment of persistent high-risk papillomavirus (hrHPV) infection of the cervix. Patients and Methods A randomized controlled trial (RCT) was conducted on patients with persistent hrHPV infection which were randomly assigned in three groups: PHPV, interferon and control. All participants were followed up at baseline, 3 months and 6 months after enrollment. The primary outcome was hrHPV clearance at 6 months post-enrollment.
